TABLE 1.
Characteristics of patients in predicting KRAS mutations.
| Characteristic | Training cohort (n = 180) | Validation cohort (n = 78) | ||
|---|---|---|---|---|
| KRAS wild type (n = 90) | KRAS mutant (n = 90) | KRAS wild type (n = 39) | KRAS mutant (n = 39) | |
| Age, years (mean ± SD) | 61.13 ± 11.26 | 64.76 ± 10.48 | 59.33 ± 10.76 | 64.18 ± 11.15 |
| Gender | ||||
| Male | 61 (67.78%) | 67 (66.67%) | 21 (53.85%) | 31 (79.49%) |
| Female | 29 (32.22%) | 23 (25.56%) | 18 (46.15%) | 8 (20.51%) |
| Smoking | ||||
| Yes | 52 (57.78%) | 64 (71.11%) | 20 (51.28%) | 30 (76.92%) |
| No | 38 (42.22%) | 26 (28.89%) | 19 (48.72%) | 9 (23.08%) |
| CEA (ng/ml) | 5.97 (3.20, 20.44) | 4.57 (2.99, 6.52) | 5.13 (2,65, 18.28) | 4.60 (3.14, 10.35) |
| EGFR | ||||
| Wild type | 46 (51.11%) | 90 (100.00%) | 21 (53.85%) | 39 (100.00%) |
| Mutant | 44 (48.89%) | 0 (0.00%) | 18 (46.15%) | 0 (0.00%) |
| SUVmax | 9.85 (6.70, 13.07) | 7.79 (5.14, 11.54) | 9.48 (7.65, 13.79) | 10.37 (6.85, 12.42) |
| MTV | 30.50 (17.34, 98.34) | 31.95 (19.02, 100.55) | 24.11 (13.81, 64.65) | 27.56 (18.94, 138.08) |
Note: CEA, carcinoembryonic antigen; SUV, standard uptake value; MTV, metabolic tumor volume.